183 related articles for article (PubMed ID: 19178670)
1. Dose-escalating vinblastine for the treatment of canine mast cell tumour.
Vickery KR; Wilson H; Vail DM; Thamm DH
Vet Comp Oncol; 2008 Jun; 6(2):111-9. PubMed ID: 19178670
[TBL] [Abstract][Full Text] [Related]
2. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
Taylor F; Gear R; Hoather T; Dobson J
J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421
[TBL] [Abstract][Full Text] [Related]
3. Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997).
Thamm DH; Mauldin EA; Vail DM
J Vet Intern Med; 1999; 13(5):491-7. PubMed ID: 10499735
[TBL] [Abstract][Full Text] [Related]
4. Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: a retrospective study in fourteen dogs with mast cell tumours.
Trumel C; Bourgès-Abella N; Touron C; Lanore D; Geffré A; Diquelou A; Guelfi JF; Braun JP
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):275-9. PubMed ID: 16050908
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation of single-agent vinblastine in dogs.
Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE
J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250
[TBL] [Abstract][Full Text] [Related]
6. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases.
Thamm DH; Turek MM; Vail DM
J Vet Med Sci; 2006 Jun; 68(6):581-7. PubMed ID: 16820715
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of vinblastine for treatment of canine mast cell tumors.
Rassnick KM; Bailey DB; Flory AB; Balkman CE; Kiselow MA; Intile JL; Autio K
J Vet Intern Med; 2008; 22(6):1390-6. PubMed ID: 19000249
[TBL] [Abstract][Full Text] [Related]
8. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
[TBL] [Abstract][Full Text] [Related]
9. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
Stanclift RM; Gilson SD
J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109
[TBL] [Abstract][Full Text] [Related]
11. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
Hahn KA; Legendre AM; Shaw NG; Phillips B; Ogilvie GK; Prescott DM; Atwater SW; Carreras JK; Lana SE; Ladue T; Rusk A; Kinet JP; Dubreuil P; Moussy A; Hermine O
Am J Vet Res; 2010 Nov; 71(11):1354-61. PubMed ID: 21034327
[TBL] [Abstract][Full Text] [Related]
13. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
Cooper M; Tsai X; Bennett P
Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648
[TBL] [Abstract][Full Text] [Related]
14. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH
J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs.
Henry CJ; Downing S; Rosenthal RC; Klein MK; Meleo K; Villamil JA; Fineman LS; McCaw DL; Higginbotham ML; McMichael J
Am J Vet Res; 2007 Nov; 68(11):1246-51. PubMed ID: 17975981
[TBL] [Abstract][Full Text] [Related]
16. Hypotonic water as adjuvant therapy for incompletely resected canine mast cell tumors: a randomized, double-blind, placebo-controlled study.
Brocks BA; Neyens IJ; Teske E; Kirpensteijn J
Vet Surg; 2008 Jul; 37(5):472-8. PubMed ID: 18986315
[TBL] [Abstract][Full Text] [Related]
17. Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).
Lejeune A; Skorupski K; Frazier S; Vanhaezebrouck I; Rebhun RB; Reilly CM; Rodriguez CO
Vet Comp Oncol; 2015 Sep; 13(3):267-80. PubMed ID: 23721492
[TBL] [Abstract][Full Text] [Related]
18. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival.
Krick EL; Billings AP; Shofer FS; Watanabe S; Sorenmo KU
Vet Comp Oncol; 2009 Jun; 7(2):130-8. PubMed ID: 19453367
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ
Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175
[TBL] [Abstract][Full Text] [Related]
20. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
Kiupel M; Webster JD; Miller RA; Kaneene JB
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
